Diagnosed Incidence of Acute Myeloid Leukemia per 100,000 People of All Ages in 2019 and 2029ttttttttttttttttttttt
Relative Sizes of the Factors Contributing to the Trend in Incident Cases of Acute Myeloid Leukemia over the Next Ten Yearsttttttttt
Epidemiology Data
Methods
Diagnosed Prevalent Cases
Diagnosed Incident Cases
FLT-3 Mutation
Lifetime DALYs Gained
Drug-Treatable Populations
Drug-Treated Populations
Reference Materials
Literature Review
Studies Included in the Analysis of Acute Myeloid Leukemia
Studies Excluded from the Analysis of Acute Myeloid Leukemia
Risk/Protective Factors
Risk/Protective Factors for Acute Myeloid Leukemia
Bibliography
Glossary
Pramilesh Tekchand Suryawanshi
Pramilesh Suryawanshi, M.P.H., is an associate epidemiologist at Clarivate. Previously, Mr. Suryawanshi worked with Pathfinder International in Lepra, the Netherlands Leprosy Relief Foundation, and the National Health Mission. He received his M.P.H. from the Tata Institute of Social Sciences in Mumbai, where he worked on several public health projects, including the assessment of social health insurance schemes. He holds a bachelor’s degree in the Indian system of medicine (Ayurveda) from Rajiv Gandhi University of Health Sciences in Karnataka.
Nishant Kumar, M.P.H.
Nishant Kumar, M.P.H., is a senior director on the Epidemiology team at Clarivate. His areas of expertise are oncology and CNS diseases, including Alzheimer’s disease and dementia. His key interests in oncology are modeling disease progression and drug-treatable incident and prevalent populations. Previously, Mr. Kumar sized patient populations for rare and niche diseases, such as graft-versus-host disease and Duchenne muscular dystrophy. He earned his M.P.H. with a concentration in epidemiology and statistics from King’s College in London and a B.Sc. (Honors) in medical studies from the University of Birmingham.